As a phase III, multicenter, double-blind study initiated in July 2020, MERMAID-1 will recruit approximately 332 MRD-positive patients with completely resected stage II–III NSCLC (AJCC 8th TNM stage) without EGFR mutations or ALK rearrangements (45). This evidence concerns the gene EGFR and non-small cell lung carcinoma.